503(B) Facility

Nivagen has recently acquired an FDA-registered 503B manufacturing facility which manufactures products under strict FDA regulated cGMP (Current Goods Manufacturing Practices) standards, to deliver and safe high-quality medicines.
Nivagen shall comply with all state and federal regulations regarding compounding medications in an Outsourcing Facility as defined by the FDA in section 503B of the Federal Food, Drug and Cosmetic Act. This state-of-the-art manufacturing and innovative delivery systems enable us to design and develop ready-to-administer injectables that set the standard for quality and clinician experience, with the goal of moving healthcare forward. For more information please visit us at www.medisourcerx.com.